CN109259031A - A kind of toxin expelling compound probiotic solid beverage and preparation method thereof - Google Patents
A kind of toxin expelling compound probiotic solid beverage and preparation method thereof Download PDFInfo
- Publication number
- CN109259031A CN109259031A CN201811114776.0A CN201811114776A CN109259031A CN 109259031 A CN109259031 A CN 109259031A CN 201811114776 A CN201811114776 A CN 201811114776A CN 109259031 A CN109259031 A CN 109259031A
- Authority
- CN
- China
- Prior art keywords
- parts
- compound probiotic
- solid beverage
- powder
- toxin expelling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 79
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 79
- 150000001875 compounds Chemical class 0.000 title claims abstract description 69
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 68
- 239000003053 toxin Substances 0.000 title claims abstract description 50
- 231100000765 toxin Toxicity 0.000 title claims abstract description 50
- 239000007787 solid Substances 0.000 title claims abstract description 48
- 235000013361 beverage Nutrition 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 48
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 32
- 235000004936 Bromus mango Nutrition 0.000 claims abstract description 17
- 235000014826 Mangifera indica Nutrition 0.000 claims abstract description 17
- 235000009184 Spondias indica Nutrition 0.000 claims abstract description 17
- 235000010355 mannitol Nutrition 0.000 claims abstract description 16
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 15
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 15
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000013078 crystal Substances 0.000 claims abstract description 15
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 15
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 15
- 241000218231 Moraceae Species 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 241001093152 Mangifera Species 0.000 claims description 16
- 241001608472 Bifidobacterium longum Species 0.000 claims description 15
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 15
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 15
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 15
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 15
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 14
- 241000219173 Carica Species 0.000 claims description 14
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 14
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 13
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 12
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 12
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 12
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 240000000249 Morus alba Species 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 108700012359 toxins Proteins 0.000 abstract description 42
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 230000002829 reductive effect Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 7
- 241000186660 Lactobacillus Species 0.000 abstract description 6
- 235000013399 edible fruits Nutrition 0.000 abstract description 6
- 229940039696 lactobacillus Drugs 0.000 abstract description 6
- 241000186000 Bifidobacterium Species 0.000 abstract description 4
- 235000019605 sweet taste sensations Nutrition 0.000 abstract description 4
- 240000006432 Carica papaya Species 0.000 abstract 1
- 240000007228 Mangifera indica Species 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 8
- 230000013872 defecation Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000002346 endotoxic effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000005027 intestinal barrier Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 229930014669 anthocyanidin Natural products 0.000 description 2
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 2
- 235000008758 anthocyanidins Nutrition 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010060926 abdominal symptom Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Abstract
The invention discloses a kind of toxin expelling compound probiotic solid beverage and preparation method thereof, which includes following raw material: Oligomeric manna sugar, galactooligosaccharide, oligofructose, compound probiotic, crystal diabetin, mango powder, banaina, papaya powder and mulberries powder.The resulting toxin expelling compound probiotic solid beverage of the present invention is faint yellow, fruit sweet taste, and in uniform powdered, the viable count of Bifidobacterium is up to 1.57 × 109CFU/g, living preparation of lactobacillus number is up to 3.0 × 109CFU/g；Can be reduced by toxins in human body, mitigate the usage amount of drug up to 90% or more for the efficient of inflammation crowd, to effect crowd's asexuality difference, inflammatory reaction can be mitigated by toxin expelling, in overall 15 days onset times；Preparation method is simple, implementation easy to operate.
Description
Technical field
The present invention relates to food processing technology fields, and in particular to a kind of toxin expelling compound probiotic solid beverage and its system
Preparation Method.
Background technique
Endotoxin is one of the important sources for causing body to be inflamed, it be Gram-negative bacteria cell wall rouge it is more
Sugar is present in the gastrointestinal tract, urogenital tract and respiratory system of people, mainly induces these cells to produce and acting on target cell
What a series of raw inflammatory mediators and cell factor showed, exothermic reaction can be caused, promote prostaglandin synthesis, promote blood vessel
The release of active material, reduces blood pressure, and activates blood coagulation system and complement, causes local anaphylaxis, influences or participate in immune response, shadow
Blood glucose and neoplasm necrosis etc. are rung, generating endotoxin and not only causing obviously to infect also leads to subclinical or chronic infection, periodontitis,
Nasosinusitis, bronchitis etc., research, which confirms that endotoxin long-term chronic stimulates, can lead to internal chronic inflammation, such as obesity, diabetes,
Tumour and other chronic diseases, seriously affect human health.And by adjusting intestinal microecology balance and enhancing intestinal mucosal barrier
Endotoxin is discharged, partition causes scorching access to invade body from inflammation.
Existing toxin expelling anti-inflammatory treatment mainly takes drugs, and such as steroidal drug: glucocorticoid, prednisone, first are strong
Dragon, dexamethasone etc., it is fragrant that non-steroidal drug mainly has aspirin, acetparaminosalol, but taking drugs more or less can be to people
Body causes toxic side effect, is unfavorable for human health, also has using food therapy and alleviates, but food therapy therapeutic effect is bad, controls
The progress for the treatment of is slow.Therefore, it is badly in need of developing a kind of food of energy toxin expelling anti-inflammatory, and accordance with tolerance is small, securely and reliably, nontoxic secondary work
With.
Summary of the invention
Aiming at the problems existing in the prior art, the purpose of the present invention is to provide a kind of toxin expelling compound probiotic solids
Beverage and preparation method thereof, the solid beverage are faint yellow, fruit sweet taste, in uniform powdered, the viable count of Bifidobacterium
Up to 1.57 × 109CFU/g, living preparation of lactobacillus number is up to 3.0 × 109CFU/g；To the efficient up to 90% or more of inflammation crowd,
It can be reduced toxins in human body, mitigate the usage amount of drug, to effect crowd's asexuality difference, it is anti-inflammation can be mitigated by toxin expelling
It answers, in overall 15 days onset times；Preparation method is simple, implementation easy to operate.
In order to achieve the above object, the present invention is achieved by the following scheme.
(1) a kind of toxin expelling compound probiotic solid beverage, including following raw material: Oligomeric manna sugar, galactooligosaccharide,
Oligofructose, compound probiotic, crystal diabetin, mango powder, banaina, papaya powder and mulberries powder.
Preferably, the compound probiotic includes: bifidobacterium longum, lactobacillus plantarum, Lactobacillus rhamnosus, acidophilus cream bar
Bacterium and bifidobacterium lactis.
Preferably, the dosage of the raw material are as follows: 13.7-14.9 parts of Oligomeric manna sugar, 3.2-4.2 parts of galactooligosaccharide, low
32.4-33.8 parts of Fructooligosaccharides, 4.0-5.2 parts of compound probiotic, 16.7-17.7 parts of crystal diabetin, 13.5-15.1 parts of mango powder,
8.0-9.2 parts of banaina, 2.4-3.2 parts of papaya powder and 0.8-2.0 parts of mulberries powder.
It is further preferred that the dosage of the raw material are as follows: 14.3 parts of Oligomeric manna sugar, 3.7 parts of galactooligosaccharide, oligomeric fruit
Sugared 33.1 parts, 4.6 parts of compound probiotic, 17.2 parts of crystal diabetin, 14.3 parts of mango powder, 8.6 parts of banaina, 2.8 parts of papaya powder
With 1.4 parts of mulberries powder.
Preferably, the compound probiotic includes: 3-5 parts of bifidobacterium longum, 3-5 parts of lactobacillus plantarum, rhamnose cream bar
3-5 parts of bacterium, lactobacillus acidophilus 0.3-0.5 and 0.3-0.5 parts of bifidobacterium lactis.
It is further preferred that bifidobacterium longum, lactobacillus plantarum, Lactobacillus rhamnosus, acidophilus in the compound probiotic
The mass ratio of lactobacillus and bifidobacterium lactis is 10:10:10:1:1.
(2) a kind of hypoglycemic preparation method with oligosaccharide probiotics solid beverage, including following preparation step: will be low
Poly- mannose, galactooligosaccharide, oligofructose, compound probiotic, crystal diabetin, mango powder, banaina, papaya powder and mulberries powder
It is uniformly mixed, obtains toxin expelling compound probiotic solid beverage.
Preferably, the compound probiotic includes: bifidobacterium longum, lactobacillus plantarum, Lactobacillus rhamnosus, acidophilus cream bar
Bacterium and bifidobacterium lactis.
Compared with prior art, the invention has the benefit that
The resulting toxin expelling compound probiotic solid beverage of the present invention is faint yellow fruit sweet taste, in uniform powdered,
The viable count of its Bifidobacterium is up to 1.57 × 109CFU/g, living preparation of lactobacillus number is up to 3 × 109CFU/g, viable count content compared with
It is high.
The resulting toxin expelling compound probiotic solid beverage induced by endotoxin accumulation crowd of the present invention has the improvement of conspicuousness to make
With induced by endotoxin accumulates the effective percentage of crowd up to 90% or more, can be reduced internal endotoxin, the usage amount of drug is reduced, to work
With crowd's asexuality difference, can no-float diet auxiliary discharge endotoxin can effectively change in overall 15 days onset times
Kind body, optimizes body vivo environment, the generation with prevention of inflammation is effectively relieved.
The resulting toxin expelling of the present invention is with probiotics (bifidobacterium longum, lactobacillus plantarum, mouse in compound probiotic solid beverage
Lee's sugar lactobacillus and lactobacillus acidophilus and bifidobacterium lactis) there is enhancing intestinal mucosal barrier, it adjusts cell pathway and endotoxin is discharged
Effect, while oligosaccharide (Oligomeric manna sugar, galactooligosaccharide, oligofructose) to probiotics have proliferation function, the two phase
Interaction significantly reduces the intracorporal endotoxin content of people.
Specific embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
It will be appreciated that the following example is merely to illustrate the present invention, and it is not construed as limiting the scope of the invention.
Embodiment 1
A kind of preparation method of toxin expelling compound probiotic solid beverage, including following preparation step:
By 14.3% Oligomeric manna sugar, 3.7% galactooligosaccharide, 33.1% oligofructose, 4.6% compound probiotic,
17.2% crystal diabetin, 14.3% mango powder, 8.6% banaina, 2.8% papaya powder and 1.4% mulberries powder are uniformly mixed, and must be arranged
Poison compound probiotic solid beverage；Wherein the bifidobacterium longum in compound probiotic, lactobacillus plantarum, Lactobacillus rhamnosus,
The mass ratio of lactobacillus acidophilus and bifidobacterium lactis is 10:10:10:1:1.
Embodiment 2
A kind of preparation method of toxin expelling compound probiotic solid beverage, including following preparation step:
By 13.0% Oligomeric manna sugar, 4.2% galactooligosaccharide, 35.2% oligofructose, 6.0% compound probiotic,
16.4% crystal diabetin, 12.9% mango powder, 8.6% banaina, 2.4% papaya powder and 1.3% mulberries powder are uniformly mixed, and must be arranged
Poison compound probiotic solid beverage；Wherein the bifidobacterium longum in compound probiotic, lactobacillus plantarum, Lactobacillus rhamnosus,
The mass ratio of lactobacillus acidophilus and bifidobacterium lactis is 2:3:3:1:1.
Embodiment 3
A kind of preparation method of toxin expelling compound probiotic solid beverage, including following preparation step:
By 11.4% Oligomeric manna sugar, 5.0% galactooligosaccharide, 36.2% oligofructose, 5.6% compound probiotic,
16.0% crystal diabetin, 13.0% mango powder, 8.8% banaina, 3.0% papaya powder and 1.0% mulberries powder are uniformly mixed, and must be arranged
Poison compound probiotic solid beverage；Wherein the bifidobacterium longum in compound probiotic, lactobacillus plantarum, Lactobacillus rhamnosus,
The mass ratio of lactobacillus acidophilus and bifidobacterium lactis is 3:5:5:1:1.
Embodiment 4
A kind of preparation method of toxin expelling compound probiotic solid beverage, including following preparation step:
By 12.9% Oligomeric manna sugar, 4.0% galactooligosaccharide, 38.0% oligofructose, 8.0% compound probiotic,
17.2% crystal diabetin, 11.0% mango powder, 6.8% banaina, 1.4% papaya powder and 0.7% mulberries powder are uniformly mixed, and must be arranged
Poison compound probiotic solid beverage；Wherein the bifidobacterium longum in compound probiotic, lactobacillus plantarum, Lactobacillus rhamnosus,
The mass ratio of lactobacillus acidophilus and bifidobacterium lactis is 3:4:4:2:1.
Embodiment 5
A kind of preparation method of toxin expelling compound probiotic solid beverage, including following preparation step:
By 15.7% Oligomeric manna sugar, 4.1% galactooligosaccharide, 36.7% oligofructose, 4.7% compound probiotic,
18.6% crystal diabetin, 11.4% mango powder, 5.7% banaina, 1.9% papaya powder and 1.2% mulberries powder are uniformly mixed, and must be arranged
Poison compound probiotic solid beverage；Wherein the bifidobacterium longum in compound probiotic, lactobacillus plantarum, Lactobacillus rhamnosus,
The mass ratio 10:10:10:2:1 of lactobacillus acidophilus and bifidobacterium lactis.
In above embodiments, mango powder and banaina are as a kind of dietary fiber, for providing anthocyanidin and assisting seasoning,
Anthocyanidin have it is anti-oxidant, enhance human immunity, prevent cardiovascular disease, anticancer, anti-inflammatory, skin care and beauty etc. it is more
Weight effect；And mango powder and banaina can enhance and adjust with oligofructose, Oligomeric manna sugar and galactooligosaccharide comprehensive function
The ability of intestinal microecology balance, the function of intestinal canal disorder symptoms such as relief of constipation, diarrhea.
The resulting toxin expelling compound probiotic solid beverage of the present invention for major ingredient, cooperates oligomeric gala with " Oligomeric manna sugar "
Two kinds of sugar, oligofructose oligosaccharide, while being aided with the Fruit powder (mango powder, banaina, papaya powder, mulberries powder) rich in polyphenol,
And bifidobacterium longum, lactobacillus plantarum, Lactobacillus rhamnosus, lactobacillus acidophilus and bifidobacterium lactis compound probiotic is cooperated to reach
Endotoxic effect is arranged, the taste of solid beverage is adjusted finally by crystal diabetin, drinks complex prebiotics solid of the invention
The mouthfeel of material is more preferably；Reach toxin expelling effect especially by following manner:
(1) it is colonized by occupy-place in the intestine, beneficial flora in paraphyte, it is thin with enteric epithelium that probiotics can secrete adhesion factor
Corresponding receptor on born of the same parents combines to play occupation time process, and pathogen is inhibited, with the adherency of intestinal mucosa, to reach row on this site
Malicious purpose.
(2) by enhancing gut barrier, biology, chemistry, immune three big protective barriers have been constructed in vivo, have prevented bacterium
With the intrusion of toxin, endotoxic generation is effectively reduced.
(3) cell-signaling pathways are adjusted in probiotics and polyphenol substance, inhibit the signal for inducing inflammatory factor and reaction logical
Road, so that signal path caused by inhibiting because of endotoxin causes inflammatory reaction.
(4) antibacterial material is generated, toxin is killed, probiotics can secrete antibacterial material, inhibit the production of pathogenic bacteria and toxin
It is raw, achieve the purpose that toxin expelling.
The resulting toxin expelling compound probiotic solid beverage of the present invention is faint yellow, fruit sweet taste, in uniform powdered,
The viable count of its Bifidobacterium reaches 1.57 × 109CFU/g (detection method refers to GB4789.35-2016), living preparation of lactobacillus number
Reach 3.0 × 109CFU/g (detection method refers to GB4789.35-2016), viable count content is higher；Its physical and chemical index and nutrition
Index is met the requirements of the standard.
The eating method of the resulting toxin expelling compound probiotic solid beverage of the present invention are as follows: the compound prebiotic equal solid drink of 7g
Material is a packet, is taken after mixing it with water 1 packet with 40 DEG C of warm water below before the meal daily, or drinks are mixed takes with warm tea, coffee etc., when drinking in every packet
The water Instant Drinks of 80-120mL are added.The resulting toxin expelling of above embodiments is used for 150 with compound probiotic solid beverage
Diabetic population carries out clinical observation, wherein women number accounts for 60%, and male's number accounts for 40%；20-40 years old number accounts for
60%, 50-60 year old number accounts for 20%, and number accounts for 20% within 60 years old or more；There is the number of 1-2 medical history to account for 40%, there is 3-5 medical history
Number account for 40%, the number of 5 years or more medical histories accounts for 20%.The result shows that the resulting toxin expelling of the present invention is solid with compound probiotic
Body beverage is efficient up to 95% or more to having toxin crowd's in vivo, and dosage auxiliary food is reduced in the people for having chronic inflammation
With the resulting toxin expelling compound probiotic solid beverage of the present invention, vivotoxin is substantially reduced；The normal number of defecation condition accounts for
80%, the number that skin improves accounts for 60%, and the number that internal inflammatory reaction mitigates accounts for 70%.
The following are the clinical effectiveness of the part typical case of toxin expelling of the present invention compound probiotic solid beverage:
Case 1
Certain is defended, female 28 years old, abdominal pain and symptom of diarrhea occurs after eating unhygienic food, takes the resulting toxin expelling of embodiment 1
After compound probiotic solid beverage 3h, abdomen does not have obvious pain, and stomach is unobstructed after taking 7 days, defecation rule.
Case 2
Mr. Wang, female, 27 years old, defecation was irregular on ordinary days, there is constipation situation, by taking the resulting toxin expelling of embodiment 1 with again
After closing probiotics solid beverage 15 days, defecation is normal, and once a day, and physical condition improves.
Case 3
Jiao, female 27 years old, there is diarrhea history, and stomach is sensitive, and skin has eczema, uses by taking the resulting toxin expelling of embodiment 1
Stomach is obviously improved after compound probiotic solid beverage 4 days, and defecation has no that the pool is dilute, and skin eczema improves after taking 15 days.
Case 4
Zhao, male, 45 years old, defecation was irregular on ordinary days, when have constipation, and have beer belly, it is resulting by taking embodiment 1
Toxin expelling is with after compound probiotic solid beverage 7 days, and defecation is more regular, no constipation and symptom of diarrhea, take 15 days postabdomens with
It is reduced before compared to waistline.
In conclusion present invention gained toxin expelling compound probiotic solid beverage has the improvement of conspicuousness to toxin buildup person
Effect, to effect crowd's asexuality difference, the number that works is most within 7 days, in overall 15 days onset times.The resulting reality of the present invention
Apply the resulting toxin expelling compound probiotic solid beverage of example 1 and contain the probiotics that can be colonized with enterocyte, by with cause a disease
Bacterium competition proliferation, inhibits the growth of pathogenic bacteria；And the function of intestinal mucosal barrier can be enhanced, prevent harmful bacteria and endotoxic invaded
Enter；The antibacterial material of probiotics secretion can also kill harmful bacteria, remove toxin, inhibit the Inflammatory Pathway of endotaxin mediate, inhibit
The generation of inflammatory reaction maintains healthy physiological status to be of great significance discharge vivotoxin.
Although the present invention is described in detail with a general description of the specific embodiments in this specification,
But on the basis of the present invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.
Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to claimed model
It encloses.
Claims (8)
1. a kind of toxin expelling compound probiotic solid beverage, which is characterized in that including following raw material: Oligomeric manna sugar, oligomeric half
Lactose, oligofructose, compound probiotic, crystal diabetin, mango powder, banaina, papaya powder and mulberries powder.
2. toxin expelling according to claim 1 compound probiotic solid beverage, which is characterized in that the compound probiotic packet
Contain: bifidobacterium longum, lactobacillus plantarum, Lactobacillus rhamnosus, lactobacillus acidophilus and bifidobacterium lactis.
3. toxin expelling according to claim 2 compound probiotic solid beverage, which is characterized in that the dosage of the raw material
Are as follows: 13.7-14.9 parts of Oligomeric manna sugar, 3.2-4.2 parts of galactooligosaccharide, 32.4-33.8 parts of oligofructose, compound probiotic
4.0-5.2 parts, 16.7-17.7 parts of crystal diabetin, 13.5-15.1 parts of mango powder, 8.0-9.2 parts of banaina, papaya powder 2.4-3.2
Part and mulberries powder 0.8-2.0 parts.
4. toxin expelling according to claim 3 compound probiotic solid beverage, which is characterized in that the dosage of the raw material
Are as follows: 14.3 parts of Oligomeric manna sugar, 3.7 parts of galactooligosaccharide, 33.1 parts of oligofructose, 4.6 parts of compound probiotic, crystal diabetin
17.2 parts, 14.3 parts of mango powder, 8.6 parts of banaina, 2.8 parts of papaya powder and 1.4 parts of mulberries powder.
5. toxin expelling according to claim 3 compound probiotic solid beverage, which is characterized in that the compound probiotic packet
Contain: 3-5 parts of bifidobacterium longum, 3-5 parts of lactobacillus plantarum, 3-5 parts of Lactobacillus rhamnosus, lactobacillus acidophilus 0.3-0.5 and cream are double
0.3-0.5 parts of discrimination bacillus.
6. toxin expelling according to claim 5 compound probiotic solid beverage, which is characterized in that in the compound probiotic
Bifidobacterium longum, lactobacillus plantarum, Lactobacillus rhamnosus, lactobacillus acidophilus and bifidobacterium lactis mass ratio be 10:10:10:
1:1。
7. a kind of hypoglycemic preparation method with oligosaccharide probiotics solid beverage, which is characterized in that including following preparation step:
By Oligomeric manna sugar, galactooligosaccharide, oligofructose, compound probiotic, crystal diabetin, mango powder, banaina, papaya powder and mulberry
Shen powder is uniformly mixed, and obtains toxin expelling compound probiotic solid beverage.
8. the hypoglycemic preparation method with oligosaccharide probiotics solid beverage according to claim 7, which is characterized in that institute
Stating compound probiotic includes: bifidobacterium longum, lactobacillus plantarum, Lactobacillus rhamnosus, lactobacillus acidophilus and bifidobacterium lactis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811114776.0A CN109259031A (en) | 2018-09-25 | 2018-09-25 | A kind of toxin expelling compound probiotic solid beverage and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811114776.0A CN109259031A (en) | 2018-09-25 | 2018-09-25 | A kind of toxin expelling compound probiotic solid beverage and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109259031A true CN109259031A (en) | 2019-01-25 |
Family
ID=65197915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811114776.0A Pending CN109259031A (en) | 2018-09-25 | 2018-09-25 | A kind of toxin expelling compound probiotic solid beverage and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109259031A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105942505A (en) * | 2016-05-13 | 2016-09-21 | 四川子仁制药有限公司 | Recipe and preparation method of quintuplet probiotic nutritional powder |
| CN106617091A (en) * | 2016-11-08 | 2017-05-10 | 广东正当年生物科技有限公司 | Probiotics and prebiotic compound preparation |
| CN107279649A (en) * | 2017-07-25 | 2017-10-24 | 杭州诺利康健康管理有限公司 | A kind of probiotics solid beverage formula and its manufacture method |
-
2018
- 2018-09-25 CN CN201811114776.0A patent/CN109259031A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105942505A (en) * | 2016-05-13 | 2016-09-21 | 四川子仁制药有限公司 | Recipe and preparation method of quintuplet probiotic nutritional powder |
| CN106617091A (en) * | 2016-11-08 | 2017-05-10 | 广东正当年生物科技有限公司 | Probiotics and prebiotic compound preparation |
| CN107279649A (en) * | 2017-07-25 | 2017-10-24 | 杭州诺利康健康管理有限公司 | A kind of probiotics solid beverage formula and its manufacture method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10501530B2 (en) | Probiotics, secretory IgA and inflammation | |
| CN109430666A (en) | A kind of Freeze-dry Powder of Probioctics solid beverage | |
| CN106954847A (en) | Ferment probiotic composition with function of relaxing bowel, using and process preparation | |
| KR20080091743A (en) | Pharmaceutical and food compositions for preventing or treating arthritis comprising lactic acid bacteria and collagen as active ingredients | |
| CN109464487A (en) | Probiotics compound of anti-helicobacter pylori and preparation method thereof | |
| CN113355255A (en) | Lactobacillus reuteri LM1071 strain and composition comprising culture thereof | |
| CN108029923A (en) | A kind of probiotics solid beverage factory formula with antiallergic effect | |
| US20060045924A1 (en) | Dried fruit composition with laxative effects and method for administration thereof | |
| CN109718289A (en) | A kind of galactooligosaccharide prebiotic compositions treating or preventing enterogastric diseases | |
| CN103156108A (en) | Fortified food for preventing and treating diabetes mellitus and hypertension diseases | |
| CN107996936A (en) | A kind of solid beverage for improving stomach health problem | |
| CN114287633B (en) | Probiotic composition containing cranberry and application thereof in helicobacter pylori resistance | |
| CN112385843A (en) | Balanced nutrition powder containing composite prebiotics and preparation method thereof | |
| CN109663116A (en) | A kind of Chinese medicine composition that treating nausea and vomiting caused by chemotherapy, free decoction granule and application | |
| CN109259031A (en) | A kind of toxin expelling compound probiotic solid beverage and preparation method thereof | |
| CN108618020A (en) | A kind of relax bowel improves the dietary food product of constipation | |
| CN114698717A (en) | Tablet candy with intestinal function adjusting function | |
| KR20220008218A (en) | Composition for preventing or treating inflammatory bowel diseases | |
| US20090110663A1 (en) | Method for treatment of bowel disorders | |
| CN109010356A (en) | Adjust intestinal flora and the anti-composition to treat constipation and its application | |
| KR20200021257A (en) | Composition for preventing or treating behcet's diseases or herpes simplex virus infection containing eubacterium rectale | |
| KR100866911B1 (en) | Compositions for Preventing or Treating Arthritis Comprising Lactic Acid Bacteria and Collagen as Active Ingredients | |
| CN104187719A (en) | Full-nutritional formula food for lymphoma | |
| CN109260235A (en) | A kind of application of composition in preparation prevention and treatment constipation drug or health care product | |
| CN107412422A (en) | A kind of oral liquid that can improve body regulatory function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190125 |